The content on this site is intended for healthcare professionals only
Multiple myeloma treatment in the Philippines has seen significant advances over the last two decades, including the use of proteasome inhibitors and immunotherapy.
Despite these improvements, financial accessibility remains a major issue, with many patients relying on basic therapies.
The number of trained haematologists is increasing, and efforts are underway to secure government insurance coverage. Immunotherapy shows promise for better survival rates, and collaboration with stakeholders is crucial for patient support.
Independent clones in CLL show oligoclonality and early evolution patterns
Understanding AL amyloidosis: Treatment and diagnosis
Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients
The need for improved healthcare infrastructure for extranodal NK/T-cell lymphoma in Latin America
Advancements in paediatric Acute lymphoblastic leukemia management
ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma
Multiple myeloma in a resource constrained setting
Haemato-oncological Cancers
Multiple myeloma (A cancer arising from plasma cells)
